Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.
Posts by this author
Vaxess Announces Launch of Phase 1 Trial For H1 Influenza Vaccine Patch
Company focused on creating shot-free future of vaccines; first human trial of Vaxess MIMIX™ vaccine patch will focus on administering influenza vaccine
Olaris CEO Elected to Personalized Medicine Coalition Board of Directors
Dr. Elizabeth O’Day will lead personalized medicine investment and adoption efforts globally during three-year term
WALTHAM, Mass., June 9, 2020 — Olaris, a precision medicine company that is working to fundamentally change how diseases are treated, today announced that The Personalized Medicine Coalition (PMC) has elected Olaris CEO and Founder Dr. Elizabeth O’Day to serve a three-year term on the PMC Board of Directors.
